Profile data is unavailable for this security.
About the company
Celcuity, Inc. is a clinical-stage biotechnology company. The Company is seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. Its therapeutic efforts are focused on developing molecularly targeted therapies that address the same cancer driver a CELsignia companion diagnostic can identify. The Company's lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Its mechanism of action and pharmacokinetic properties are highly differentiated from other investigational therapies that target PI3K or mTOR alone or together. Its initial clinical development program for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), HER2-negative, advanced, or metastatic breast cancer. The Company's additional clinical development programs focus on various other tumor types.
- Revenue in USD (TTM)0.00
- Net income in USD-40.37m
- Incorporated2017
- Employees45.00
- LocationCelcuity Inc16305 36th Ave N Ste 100MINNEAPOLIS 55446-4285United StatesUSA
- Phone+1 (763) 392-0767
- Fax+1 (302) 655-5049
- Websitehttp://celcuity.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMV Pharmaceuticals Inc | 0.00 | -73.32m | 218.80m | 62.00 | -- | 0.8893 | -- | -- | -1.61 | -1.61 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -24.36 | -- | -25.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.75 | -- | -- | -- |
| Pyxis Oncology Inc | 0.00 | -120.72m | 221.88m | 75.00 | -- | 1.31 | -- | -- | -3.65 | -3.65 | 0.00 | 4.58 | 0.00 | -- | -- | 0.00 | -49.13 | -- | -54.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -58.89 | -- | -- | -- |
| Petro Usa Inc | 0.00 | -19.82k | 222.03m | -- | -- | -- | -- | -- | -0.0635 | -0.0635 | 0.00 | -0.0006 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -69.79 | -- | -- | -- | -- | 53.07 | -- | -- | -- |
| Cabaletta Bio Inc | 0.00 | -52.98m | 222.52m | 58.00 | -- | 2.00 | -- | -- | -1.80 | -1.80 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -43.55 | -34.04 | -47.00 | -35.73 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | -- | -- |
| Kezar Life Sciences Inc | 0.00 | -68.24m | 223.74m | 84.00 | -- | 0.802 | -- | -- | -1.01 | -1.01 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -26.37 | -29.68 | -27.39 | -30.93 | -- | -- | -- | -- | -- | -- | 0.0352 | -- | -- | -- | -24.91 | -- | 32.32 | -- |
| Icosavax Inc | 2.65m | -86.33m | 224.24m | 34.00 | -- | 0.9909 | -- | 84.56 | -2.19 | -2.19 | 0.0672 | 5.67 | 0.0097 | -- | -- | 78,000.00 | -31.70 | -- | -32.98 | -- | -- | -- | -3,255.17 | -- | -- | -- | 0.00 | -- | 382.80 | -- | -255.21 | -- | -- | -- |
| Celcuity Inc | 0.00 | -40.37m | 224.59m | 45.00 | -- | 1.68 | -- | -- | -2.61 | -2.61 | 0.00 | 6.17 | 0.00 | -- | -- | 0.00 | -30.86 | -37.87 | -32.01 | -39.28 | -- | -- | -- | -- | -- | -40.24 | 0.2073 | -- | -- | -- | -36.36 | -- | -7.92 | -- |
| Fennec Pharmaceuticals Inc | 0.00 | -21.28m | 224.67m | 10.00 | -- | 80.06 | -- | -- | -0.8168 | -0.8168 | 0.00 | 0.1068 | 0.00 | -- | -- | 0.00 | -75.43 | -59.18 | -82.67 | -64.40 | -- | -- | -- | -38,331.77 | -- | -32.69 | 0.8992 | -- | -100.00 | -- | 4.21 | -- | -- | -- |
| OptiNose Inc | 76.28m | -74.83m | 225.86m | 141.00 | -- | -- | -- | 2.96 | -0.8805 | -0.8805 | 0.888 | -0.5079 | 0.4916 | 0.8702 | 2.20 | 540,964.60 | -48.23 | -50.54 | -206.93 | -70.99 | 87.86 | 86.43 | -98.11 | -195.92 | 0.7332 | -3.19 | 1.79 | -- | 2.18 | -- | 9.07 | -- | -51.74 | -- |
| Gritstone bio Inc | 19.95m | -119.69m | 227.04m | 233.00 | -- | 1.32 | -- | 11.38 | -1.38 | -1.38 | 0.2304 | 1.97 | 0.0769 | -- | 19.47 | 85,600.86 | -46.13 | -43.63 | -53.90 | -49.39 | -- | -- | -600.09 | -590.74 | -- | -- | 0.1018 | -- | -58.63 | -- | -59.41 | -- | -12.61 | -- |
| Benson Hill Inc | 381.23m | -99.70m | 227.55m | 440.00 | -- | 1.17 | -- | 0.5969 | -0.5497 | -0.7007 | 2.12 | 0.9382 | 0.7361 | 6.82 | 12.04 | 866,438.60 | -19.25 | -- | -22.88 | -- | 0.9252 | -- | -26.15 | -- | 2.58 | -5.83 | 0.354 | -- | 319.19 | -- | 18.41 | -- | -- | -- |
| Savara Inc | 0.00 | -39.16m | 232.65m | 22.00 | -- | 2.00 | -- | -- | -0.2668 | -0.2668 | 0.00 | 1.02 | 0.00 | -- | -- | 0.00 | -23.38 | -40.84 | -24.54 | -43.63 | -- | -- | -- | -103,079.80 | -- | -14.06 | 0.1825 | -- | -100.00 | -- | 13.30 | -- | 48.10 | -- |
| Rigel Pharmaceuticals Inc | 120.24m | -58.57m | 232.70m | 155.00 | -- | -- | -- | 1.94 | -0.3383 | -0.3383 | 0.7322 | -0.0785 | 0.7973 | 0.2223 | 4.31 | 775,754.80 | -38.84 | -35.25 | -67.78 | -53.08 | 98.55 | 98.98 | -48.71 | -50.55 | 1.64 | -17.94 | 1.53 | -- | -19.43 | 93.05 | -226.97 | -- | 22.37 | -- |
| Actinium Pharmaceuticals Inc | 1.05m | -30.38m | 233.17m | 32.00 | -- | 3.24 | -- | 221.44 | -1.30 | -1.30 | 0.0452 | 2.83 | 0.0105 | -- | -- | 32,906.25 | -30.18 | -73.21 | -32.19 | -87.46 | -- | -- | -2,885.09 | -10,414.62 | -- | -- | 0.00007 | -- | -- | -- | -11.51 | -- | 17.27 | -- |
Data as of Mar 30 2023. Currency figures normalised to Celcuity Inc's reporting currency: US Dollar USD
36.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2022 | 1.40m | 6.46% |
| Commodore Capital LPas of 31 Dec 2022 | 1.33m | 6.13% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2022 | 1.21m | 5.59% |
| Morgan Stanley & Co. LLCas of 31 Dec 2022 | 1.02m | 4.72% |
| Frontier Wealth Management LLCas of 30 Jun 2022 | 731.80k | 3.38% |
| PFM Health Sciences LPas of 31 Dec 2022 | 712.11k | 3.29% |
| CapFinancial Partners LLCas of 31 Dec 2022 | 630.91k | 2.91% |
| Millennium Management LLCas of 31 Dec 2022 | 440.48k | 2.03% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 426.83k | 1.97% |
| Jacob Asset Management of New York LLCas of 31 Dec 2022 | 73.21k | 0.34% |
More ▼
Data from 30 Jun 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
